Tysabri Accelerated Approval Based On Strength Of Effect, FDA Review Shows
This article was originally published in Pharmaceutical Approvals Monthly
The degree of Tysabri's treatment effect in multiple sclerosis was integral to FDA's decision to grant the agent accelerated approval, review documents show
You may also be interested in...
Tysabri withdrawal effects: GlaxoSmithKline, Antisense Therapeutics halt MS drug Phase II trials, citing identical mechanism of action. Teva, Serono, Schering jockey for advantage over Biogen Idec following additional reports of PML in Tysabri recipients, addition of Avonex liver warning
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011